MX357169B - Biomarcadores de diabetes. - Google Patents
Biomarcadores de diabetes.Info
- Publication number
- MX357169B MX357169B MX2014014348A MX2014014348A MX357169B MX 357169 B MX357169 B MX 357169B MX 2014014348 A MX2014014348 A MX 2014014348A MX 2014014348 A MX2014014348 A MX 2014014348A MX 357169 B MX357169 B MX 357169B
- Authority
- MX
- Mexico
- Prior art keywords
- diabetes
- central memory
- cells
- cd45ro
- cd62l
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 5
- 239000000090 biomarker Substances 0.000 title 1
- 210000003071 memory t lymphocyte Anatomy 0.000 abstract 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 abstract 3
- 102100033467 L-selectin Human genes 0.000 abstract 3
- 230000005784 autoimmunity Effects 0.000 abstract 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 2
- 208000001280 Prediabetic State Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 238000010185 immunofluorescence analysis Methods 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ecology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651144P | 2012-05-24 | 2012-05-24 | |
| PCT/US2013/042627 WO2013177505A1 (en) | 2012-05-24 | 2013-05-24 | Diabetes biomarkers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014014348A MX2014014348A (es) | 2015-06-05 |
| MX357169B true MX357169B (es) | 2018-06-28 |
Family
ID=49621783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014348A MX357169B (es) | 2012-05-24 | 2013-05-24 | Biomarcadores de diabetes. |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20130316375A1 (https=) |
| EP (2) | EP2856149B1 (https=) |
| JP (5) | JP6312332B2 (https=) |
| KR (1) | KR102172285B1 (https=) |
| CN (1) | CN104520707B (https=) |
| AU (4) | AU2013266145A1 (https=) |
| CA (1) | CA2874507A1 (https=) |
| DK (1) | DK2856149T3 (https=) |
| ES (1) | ES2810227T3 (https=) |
| IN (1) | IN2014DN10259A (https=) |
| MX (1) | MX357169B (https=) |
| WO (1) | WO2013177505A1 (https=) |
| ZA (1) | ZA201409006B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| US20130316375A1 (en) * | 2012-05-24 | 2013-11-28 | Orban Biotech Llc | Diabetes biomarkers |
| KR20150033703A (ko) | 2012-06-27 | 2015-04-01 | 오르반 바이오테크 엘엘씨 | 당뇨병 치료를 위한 ctla4 융합 단백질 |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| WO2016103390A1 (ja) * | 2014-12-25 | 2016-06-30 | 株式会社日立製作所 | インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 |
| CN105567851A (zh) * | 2016-02-29 | 2016-05-11 | 北京泱深生物信息技术有限公司 | 一种与糖尿病相关的分子标志物 |
| WO2017162759A1 (en) * | 2016-03-22 | 2017-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits of assessing status, risk or prognosis of type 1 diabetes |
| WO2021260654A1 (en) | 2020-06-26 | 2021-12-30 | Phaim Pharma Ltd | Psoriasis and other autoimmune diseases antigen immune modulator (aim) therapeutic platform |
| US20240277768A1 (en) | 2021-06-17 | 2024-08-22 | Tihamer Orban | Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2007037544A1 (ja) * | 2005-09-30 | 2009-04-16 | 国立大学法人京都大学 | 制御性ｔ細胞の製造を向上させる薬剤のスクリーニング方法の開発、及び免疫抑制性のマクロライド系抗生剤を用いる制御性ｔ細胞の製造方法 |
| WO2009120341A2 (en) * | 2008-03-24 | 2009-10-01 | University Of South Florida | Biomarkers for predicting response to immunosuppressive therapy |
| US20100080784A1 (en) * | 2008-09-12 | 2010-04-01 | Torrey Pines Institute For Molecular Studies | Methods for treating cachexia and lymphopenia |
| US20130316375A1 (en) * | 2012-05-24 | 2013-11-28 | Orban Biotech Llc | Diabetes biomarkers |
| JP7618502B2 (ja) * | 2021-05-14 | 2025-01-21 | 東京計器株式会社 | 船舶用自動操舵装置 |
-
2013
- 2013-03-14 US US13/803,581 patent/US20130316375A1/en not_active Abandoned
- 2013-05-24 JP JP2015514216A patent/JP6312332B2/ja active Active
- 2013-05-24 DK DK13794110.0T patent/DK2856149T3/da active
- 2013-05-24 CA CA2874507A patent/CA2874507A1/en active Pending
- 2013-05-24 EP EP13794110.0A patent/EP2856149B1/en active Active
- 2013-05-24 ES ES13794110T patent/ES2810227T3/es active Active
- 2013-05-24 AU AU2013266145A patent/AU2013266145A1/en not_active Abandoned
- 2013-05-24 EP EP20184212.7A patent/EP3767295A1/en active Pending
- 2013-05-24 KR KR1020147036002A patent/KR102172285B1/ko active Active
- 2013-05-24 CN CN201380027247.6A patent/CN104520707B/zh not_active Expired - Fee Related
- 2013-05-24 WO PCT/US2013/042627 patent/WO2013177505A1/en not_active Ceased
- 2013-05-24 MX MX2014014348A patent/MX357169B/es active IP Right Grant
-
2014
- 2014-12-02 IN IN10259DEN2014 patent/IN2014DN10259A/en unknown
- 2014-12-08 ZA ZA2014/09006A patent/ZA201409006B/en unknown
-
2016
- 2016-06-17 US US15/185,831 patent/US20160299128A1/en not_active Abandoned
-
2018
- 2018-02-19 JP JP2018027381A patent/JP6761827B2/ja not_active Expired - Fee Related
- 2018-12-28 US US16/235,556 patent/US20190137483A1/en not_active Abandoned
-
2019
- 2019-02-07 AU AU2019200824A patent/AU2019200824B2/en not_active Ceased
-
2020
- 2020-09-07 JP JP2020150183A patent/JP2021001899A/ja active Pending
-
2021
- 2021-04-28 AU AU2021202609A patent/AU2021202609A1/en not_active Abandoned
-
2022
- 2022-11-02 JP JP2022175993A patent/JP2023011814A/ja active Pending
-
2023
- 2023-04-27 US US18/140,214 patent/US20230333094A1/en not_active Abandoned
- 2023-08-31 AU AU2023222980A patent/AU2023222980A1/en not_active Abandoned
-
2024
- 2024-07-25 JP JP2024120652A patent/JP2024150702A/ja active Pending
-
2025
- 2025-04-10 US US19/175,610 patent/US20250237643A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6761827B2 (ja) | 2020-09-30 |
| EP2856149A4 (en) | 2016-06-01 |
| JP2018116061A (ja) | 2018-07-26 |
| KR20150022878A (ko) | 2015-03-04 |
| MX2014014348A (es) | 2015-06-05 |
| AU2019200824A1 (en) | 2019-04-04 |
| US20160299128A1 (en) | 2016-10-13 |
| AU2023222980A1 (en) | 2023-09-21 |
| US20250237643A1 (en) | 2025-07-24 |
| JP2021001899A (ja) | 2021-01-07 |
| DK2856149T3 (da) | 2020-08-17 |
| CA2874507A1 (en) | 2013-11-28 |
| US20130316375A1 (en) | 2013-11-28 |
| KR102172285B1 (ko) | 2020-11-02 |
| JP2024150702A (ja) | 2024-10-23 |
| ES2810227T3 (es) | 2021-03-08 |
| US20190137483A1 (en) | 2019-05-09 |
| EP2856149B1 (en) | 2020-07-08 |
| US20230333094A1 (en) | 2023-10-19 |
| JP2015520378A (ja) | 2015-07-16 |
| IN2014DN10259A (https=) | 2015-08-07 |
| AU2021202609A1 (en) | 2021-05-27 |
| CN104520707B (zh) | 2018-03-27 |
| JP2023011814A (ja) | 2023-01-24 |
| CN104520707A (zh) | 2015-04-15 |
| AU2013266145A1 (en) | 2015-01-15 |
| ZA201409006B (en) | 2016-07-27 |
| AU2019200824B2 (en) | 2021-06-24 |
| JP6312332B2 (ja) | 2018-04-18 |
| WO2013177505A1 (en) | 2013-11-28 |
| EP3767295A1 (en) | 2021-01-20 |
| EP2856149A1 (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX357169B (es) | Biomarcadores de diabetes. | |
| MX382244B (es) | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales | |
| WO2012149493A3 (en) | Hsp90 combination therapy | |
| MY175351A (en) | Method and kit for measurement of nk cell activity | |
| WO2011135194A3 (en) | Method for diagnosing risk of type 1 diabetes and for preventing onset of type 1 diabetes | |
| MA33747B1 (fr) | Anticorps monoclonaux diriges contre la progastrine et leurs utilisations | |
| MX2013000917A (es) | Metodos para detectar las enfermedades o condiciones usando celulas fagociticas. | |
| EP2522984A3 (en) | Method and apparatus for post-sequestration monitoring and management of carbon dioxide | |
| WO2013071119A3 (en) | Methods for treating, diagnosing and monitoring alzheimer's disease | |
| MX388168B (es) | Un anticuerpo anti-amiloide beta (a?) monoclonal humanizado para usarse en el tratamiento de enfermedad de alzheimer. | |
| GB201009641D0 (en) | Methods of monitoring conditions by sequence analysis | |
| MX343555B (es) | Métodos de tratamiento de diabetes con antagonistas de ligando tipo delta 4. | |
| WO2019105468A8 (en) | Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody | |
| PH12014502436A1 (en) | In vitro method for the diagnosis and surveillance of cancer | |
| WO2011140208A3 (en) | Methods and compositions for diagnosing and treating autoimmune disorders | |
| WO2011085057A3 (en) | Methods for detecting insulin autoantibody | |
| WO2012006056A3 (en) | Ccr6 as a biomarker of alzheimer's disease | |
| WO2009049228A3 (en) | Compositions and methods for assessing disorders | |
| EP3219813A3 (en) | Methods for treating, diagnosing, and monitoring lupus | |
| EP4286847A3 (en) | Genetic abnormalities in plasma cell dyscrasias | |
| WO2011133036A3 (en) | Means and methods for determining risk of cardiovascular disease | |
| PH12014501445A1 (en) | Detection of human umbilical cord tissue-derived cells | |
| TW200639404A (en) | Method of assessing the effectiveness of a treatment regimen | |
| GB201114909D0 (en) | Biomarkers for lysosomal storage disorders | |
| WO2006110748A3 (en) | Response gene to complement 32 (rgc-32) in disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |